← Eichor
Condition: Metastatic Hormone Sensitive Prostate Cancer Mhspc Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Metastatic Hormone Sensitive Prostate Cancer Mhspc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Comparing a 6-month vs Long-term Course of Rezvilutamide With ADT Plus Chemotherapy in mHSPC
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05956639An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic H
Phase 2 · 67 location(s) · Novartis Pharmaceuticals · NCT06991556FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer,
Phase 2 · 6 location(s) · Northwestern University · NCT06244004Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06350825The Case of "Triple" Versus "Double" Therapy for Patients With High Volume Metastatic Hormone Sensitive Prostate Cancer
Phase N/A · 2 location(s) · Uppsala University · NCT06446401Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT04734730Study on Triple Therapy Combined With HIFU for High-Tumor-Burden mHSPC
NA · 1 location(s) · Qilu Hospital of Shandong University · NCT07172685Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivati
Phase 2 · 3 location(s) · Mayo Clinic · NCT06378866Intermittent Darolutamide Treatment in the Triple Therapy of mHSPC
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06177015Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
Phase 3 · 25 location(s) · UNICANCER · NCT06496581Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inh
Phase 1 · 16 location(s) · Amgen · NCT07140900ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Phase 3 · 32 location(s) · Karolinska Institutet · NCT03903835A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
Phase N/A · 1 location(s) · Janssen Cilag S.A.S. · NCT07451002Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer
Phase 2 · 1 location(s) · University of Utah · NCT07216248Quality of Life, Functional and Cognitive Outcomes in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Phase N/A · 2 location(s) · Ankara Etlik City Hospital · NCT07181122A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT07241416Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastati
Phase 3 · 195 location(s) · Alliance for Clinical Trials in Oncology · NCT06931340A Study to Learn About How Safe Darolutamide is and How Well it Works in Combination With Androgen Deprivation Therapy a
Phase N/A · 1 location(s) · Bayer · NCT06661122TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulm
Phase 1/Phase 2 · 31 location(s) · Novartis Pharmaceuticals · NCT07190300A Study to Learn About Real-world Utilization and Outcomes of Darolutamide and Other Androgen Receptor Pathway Inhibitor
Phase N/A · 1 location(s) · Bayer · NCT07406282Multimodal Approach in Patients With mHSPC. Randomized Trial of APA+ADT vs APA-ADT and Local Treatment
NA · 3 location(s) · Fondazione IRCCS Istituto Nazionale dei Tumori, Milano · NCT05649943PROCARE - PROstate Cancer Real World Evidence Registry
Phase N/A · 53 location(s) · UroTrials Company (GmbH) · NCT06835218How Darolutamide Plus Hormone Therapy Works for Men With Advanced Prostate Cancer in Everyday Medical Practice in German
Phase N/A · 1 location(s) · Bayer · NCT07395804Comparing the Efficacy and Safety of Rezvilutamide+ADT+Docetaxel Versus Rezvilutamide +ADT in the mHSPC
Phase 3 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT05983783
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.